PDGF-DD is produced by many aggressive cancers and binds to PDGFR-β expressed on tumor cells to induce protumorigenic signaling pathways that are thought to be associated with poor patient outcome (38–42, 97). This evidence concerns the gene PDGFRB and neoplasm.